Breaking News, Trials & Filings

FDA Approves AstraZeneca Oral Treatment for Lymphocytic Leukemia and Lymphoma

Calquence will be the first all-oral, fixed-duration regimen for CLL and SLL in the U.S.

Author Image

By: Patrick Lavery

Content Marketing Editor

The FDA has approved AstraZeneca’s Calquence (acalabrutinib), for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Combined with venetoclax (brand name Venclexta, Abbvie/Genentech), it is the U.S.’ first all-oral, fixed-duration regimen for CLL and SLL. In a press release, AstraZeneca said that results from a Phase III trial (AMPLIFY) informed the FDA’s decision. These results were presented at the American Society of Hematology 2024 and published i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters